ropivacaine hydrochloride: clinical use

Prescribing considerations

• Use only in an appropriately staffed and equipped setting under an experienced regional-anaesthesia clinician.
• Take precautions against intravascular or unintended intrathecal administration and stop administration if toxicity develops.
• Give special attention to older or clinically frail patients and those with conduction abnormalities, advanced liver disease, severe renal dysfunction, acidosis or low plasma proteins.
• Avoid continuous intra-articular infusion because safety and efficacy are not established and chondrolysis has been reported.
• Neonates have slower, more variable elimination and require enhanced observation.

Contraindications and cautions

• Hypersensitivity to ropivacaine, another amide local anaesthetic or a formulation excipient
• General contraindications to the intended regional or neuraxial technique
• Intravenous regional anaesthesia
• Obstetric paracervical anaesthesia
• Hypovolaemia

Monitoring

• Observe cardiovascular and respiratory status, consciousness and early neurological signs of systemic toxicity.
• Consider ECG monitoring with class III antiarrhythmics or significant cardiac disease.
• Monitor block extent, motor recovery, pain control, blood pressure and bladder function.
• In neonates, monitor for systemic toxicity and delayed local neurological recovery during and after infusion.

Clinical pharmacology

Ropivacaine is the S-enantiomer of a long-acting amide local anaesthetic. It blocks voltage-dependent sodium conduction in nerves, is highly protein-bound, undergoes extensive hepatic metabolism—principally involving CYP1A2—and is excreted mainly as urinary metabolites. Epidural absorption is biphasic, and systemic exposure depends on the vascularity and site of administration.

Formulation and product differences

• The selected products are clear, colourless parenteral solutions; one is labelled for injection or infusion and the other for infusion.
• Presentations include single-use bottles or infusion bags, with differing sodium content and container sizes.
• The infusion presentation is preservative-free and intended for single use; inspect solutions and containers before administration.
• Ropivacaine has poor solubility in alkaline conditions, so compatibility must be checked before mixing.

Solution for infusion

Route: Intravenous

Strengths: 2 mg/mL

Injection

Route: Parenteral

Strengths: 2 mg/mL